Lobbyists are deciphering the impact of President Donald Trump’s flurry of executive orders, especially his most recent buy-American order, on drug prices and supplies. Generic drug makers are using the order to argue for guaranteed higher prices in long-term government contracts, while hospital pharmacies try to stop the order from disrupting their drug supply chains. The president and industry disagree over both the significance of the order and whether it will raise drug prices. The order does not affect Medicare...